Skip to main content

HOPA Abstracts

Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen-Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study

Abstract #CR06

Evaluating Patient Hesitancy in Receiving a Second Dose of Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Prevention After a Food and Drug Administration Dosing Recommendation Update

Abstract #CR07

First-Line Nivolumab + Ipilimumab + Chemotherapy Versus Chemotherapy Alone in Metastatic Non–Small Cell Lung Cancer: CheckMate 9LA 4-Year Clinical Update

Abstract #CR08

Impact of Frailty on Outcomes After CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Abstract #CR09

Improving Post-Transplant Vaccination Compliance via Implementation of a Clinical Pharmacist–Managed Service

Abstract #CR10

Incidence and Outcomes of Pneumonitis/Interstitial Lung Disease in Patients Receiving Trastuzumab Deruxtecan

Abstract #CR11

Pharmacist-Led Monitoring for Patients Initiating PARP Inhibitor Therapy

Abstract #CR16

Number-Needed-to-Treat Analyses of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

Abstract #CR13

Patient Perspective: Logistics of Intravenous Iron Administration and Adherence to Therapy

Abstract #CR15

Predictive Factors of Dose Reduction Among Patients Treated With Palbociclib for Advanced or Metastatic Breast Cancer in a Real-World Setting

Abstract #CR17

Page 7 of 15
Results 61 - 70 of 146